Medicare billing address
CMS Medicare provider billing file
1121 E 3900 SSuite C230
Salt Lake City, UT 84124
CMS public data · NPI 1205148061
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
James Shortridge, DO
Specialty
Credential
DO
NPI
1205148061
Primary source state
UT
Data retrieval date
July 27, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for James Shortridge, DO from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
1121 E 3900 SCMS Doctors & Clinicians file
5131 S Cottonwood StIn the 2024 CMS provider billing file, this NPI had 297 Medicare beneficiaries and 78,139 total services. The average beneficiary age was 73, and the average HCC risk score was 1.9.
Total Medicare allowed amount
$2,113,372.29
Total Medicare payment amount
$1,680,867.53
Medicare beneficiaries
297
Total services
78,139
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hypertension
66%
CMS beneficiary-panel share
Hyperlipidemia
55%
CMS beneficiary-panel share
Diabetes
34%
CMS beneficiary-panel share
Chronic kidney disease
30%
CMS beneficiary-panel share
Mood disorders
29%
CMS beneficiary-panel share
Depression
27%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, denosumab, 1 mg | 4,260 | $25.58 |
| Injection, aprepitant, 1 mg | 4,030 | $1.69 |
| Injection, dexamethasone sodium phosphate, 1 mg | 847 | $0.11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 686 | $7.49 |
| Blood test, comprehensive group of blood chemicals | 644 | $10.19 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 484 | $119.43 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 213 | $84.66 |
| Gammaglobulin (immune system protein) measurement | 191 | $9.11 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 182 | $15.70 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 165 | $25.98 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1205148061. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Anastrozole | Anastrozole | 102 | 268 | $1,696.22 |
| 2 | Tamoxifen Citrate | Tamoxifen Citrate | 76 | 193.5 | $1,720.96 |
| 3 | Calquence | Acalabrutinib Maleate | 64 | 64 | $920,663.62 |
| 4 | Revlimid | Lenalidomide | 57 | 57 | $1,044,164.78 |
| 5 | Ibrance | Palbociclib | 53 | 53 | $770,048.35 |
| 6 | Imbruvica | Ibrutinib | 53 | 53 | $600,913.83 |
| 7 | Lenalidomide | Lenalidomide | 40 | 40 | $653,439.78 |
| 8 | Eliquis | Apixaban | 38 | 52.2 | $30,929.68 |
| 9 | Hydroxyurea | Hydroxyurea | 38 | 91.4 | $1,286.00 |
| 10 | Prochlorperazine Maleate | Prochlorperazine Maleate | 34 | 34 | $331.36 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
2010
Group/practice field
Utah Cancer Specialists Pc
Telehealth reported
Yes
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.